help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on June 17, 2008
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2008-0746
A more recent version of this article appeared on September 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
93/9/3627    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Dostálová, I.
Right arrow Articles by Haluzík, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dostálová, I.
Right arrow Articles by Haluzík, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Eating Disorders
Hazardous Substances DB
*LIOTHYRONINE
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Female Endocrinology
Right arrow Metabolism

Submitted on April 4, 2008
Accepted on June 5, 2008

Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa

Ivana Dostálová, Petra Kaválková, Denisa Haluzíková, Zdena Lacinová, Milos Mráz, Hana Papezová, and Martin Haluzík*

3rd Department of Medicine, Department of Sports Medicine, Department of Psychiatry, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

* To whom correspondence should be addressed. E-mail: mhalu{at}lf1.cuni.cz.

CONTEXT: Fibroblast growth factor 19 and 21 (FGF19 and FGF21) are novel metabolic regulators that improve insulin sensitivity and decrease adiposity in mice. However, little is known about the nutritional regulation of these factors in humans. OBJECTIVE: The objective of this study was to measure plasma FGF19 and FGF21 levels in patients with anorexia nervosa (AN) and to explore its relationship with anthropometric and endocrine parameters. DESIGN: This was a single centre cross-sectional study. SETTING: Study was performed in a university hospital. PATIENTS: Seventeen untreated women with a restrictive type of AN and seventeen healthy women (C) were included. MAIN OUTCOME MEASURES: Fasting plasma FGF19 and FGF21, serum insulin, leptin, soluble leptin receptor, adiponectin, resistin, and C-reactive protein were the main outcome measures. RESULTS: Plasma FGF19 levels did not significantly differ between the groups studied, whereas plasma FGF21 levels were significantly reduced in AN relative to C group. Plasma FGF21 positively correlated with body mass index, serum leptin and insulin and was inversely related to serum adiponectin in both groups. In contrast, plasma FGF19 was not related to any of parameters studied. Partial realimentation significantly reduced plasma FGF21 levels in AN. CONCLUSION: Circulating levels of FGF21 but not FGF19 are strongly related to body weight and serum levels of leptin, adiponectin and insulin in both anorectic and normal-weight women. We suggest that reduced plasma FGF21 levels could be involved in the pathophysiology of AN or in a complex adaptive response to this disease.


Key words: fibroblast growth factor 19 • fibroblast growth factor 21 • anorexia nervosa • body mass index • leptin • adiponectin • insulin







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society